Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06355934Recruiting
Observational study of ATTR amyloidosis treatment patterns
This study looks at the health records of people with ATTR amyloidosis to understand how the disease is treated and what happens over time. It helps doctors learn more about this condition so they can improve care.
Eden Prairie, MinnesotaAges Any age - NCT06342466RecruitingPhase 2
Study of bortezomib, pomalidomide, and dexamethasone for AL amyloidosis
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Beijing, Beijing MunicipalityAges 18–90 - NCT06354322Recruiting
Genetic study for unclassified autoinflammatory disease or AA amyloidosis
This study looks for genetic causes of hard-to-diagnose autoinflammatory diseases or a related condition called AA amyloidosis. It aims to find answers for people whose condition does not fit any known type, by studying their genes and medical history.
ParisAges 3–80 - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT06197165Recruiting
Shiatsu for amyloidosis symptoms and quality of life
This study tests whether shiatsu (a gentle Japanese touch therapy) can improve symptoms and quality of life for people with amyloidosis. If you have a bothersome symptom like pain, shortness of breath, or anxiety, this trial may help you feel better.
CréteilAges 18 years+ - NCT06129656Recruiting
Cardiac Amyloidosis Registry at Leipzig Hospital
This study is a registry that collects information from people with cardiac amyloidosis. It helps doctors learn more about the condition and how to better treat it.
Leipzig, SaxonyAges Any age - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Tucson, ArizonaAges 18–90 - NCT06096675Recruiting
Physical activity study for cardiac amyloidosis patients
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
Charlotte, North CarolinaAges 18 years+ - NCT06082050RecruitingEarly Phase 1
YOLT-201 for transthyretin heart disease
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
Hangzhou, ZhejiangAges 18–80 - NCT05950867Recruiting
Testing how common wild-type TTR heart amyloidosis is
This study looks at how often a specific type of heart condition (wild-type TTR cardiac amyloidosis) occurs in people whose nerve symptoms have no clear cause. The results may help doctors spot this treatable problem earlier when neuropathy is unexplained.
Jette, Belgium Capital CityAges 60 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT05898646RecruitingPhase 2
Daratumumab maintenance for AL amyloidosis after initial treatment
This Phase 2 trial studies whether giving daratumumab as ongoing maintenance therapy after your initial AL amyloidosis treatment can improve survival. It may help by keeping the disease under control longer after you have responded to induction therapy.
Scottsdale, ArizonaAges 18 years+ - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT05760287Recruiting
Study of heart ultrasound findings in cardiac amyloidosis
This study looks at how cardiac amyloidosis shows up on heart imaging, especially ultrasound (echocardiography). It may help doctors better describe and track the condition using your exam and test results.
Roma, RMAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Duarte, CaliforniaAges 18 years+ - NCT05577819Recruiting
Screening for ATTR heart amyloid in older HFpEF patients
This study looks at how often a specific heart condition (ATTR amyloid) occurs in people age 65+ who have HFpEF. It also tries to predict who might have it, using a special heart scan, and may help your care team identify it earlier.
Boston, MassachusettsAges 65 years+ - NCT05444920Recruiting
Web network for people with amyloidosis in Italy
This trial builds an Italian online network to learn from people who may have amyloidosis (an abnormal protein condition). It collects information from participating centers and could help doctors better understand different types of amyloidosis.
Legnano, MIAges 18–99 - NCT05139797Recruiting
AI-guided heart ultrasound screening for suspected amyloidosis
This study tests whether an artificial-intelligence system can help decide who should get a special heart workup for a rare disease called cardiac amyloidosis. If you have signs that make doctors suspect this, the AI-guided ultrasound screening may help find it sooner.
Los Angeles, CaliforniaAges 18 years+ - NCT05101304Recruiting
European registry for people with amyloidosis
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
CréteilAges Any age - NCT04667494RecruitingPhase 4
Ultrasound treatment for heart amyloidosis
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Boston, MassachusettsAges 18–90 - NCT04535349Recruiting
Imaging heart uptake of bone tracer in ATTR amyloidosis
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
CaenAges 18–100 - NCT04210791Enrolling by invitation
Stem cell transplant using your own cells for AL amyloidosis
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
Nanjing, JiangsuAges 18–75 - NCT02798705Recruiting
Testing heart tiny blood vessel function in amyloidosis
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
SeoulAges 18–85 - NCT07638683RecruitingPhase 2
Teclistamab and Daratumumab for New Multiple Myeloma With Amyloidosis
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
ShanghaiAges 18 years+
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 150 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.